Your browser doesn't support javascript.
loading
Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective.
Atienza, Leonardo Garcia; Berger, Jonathan; Mei, Xiaonan; Shah, Malay B; Daily, Michael F; Grigorian, Alla; Gedaly, Roberto.
Afiliación
  • Atienza LG; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Berger J; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Mei X; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Shah MB; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Daily MF; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Grigorian A; Division of Hepatology, Department of Internal Medicine, University of Kentucky, College of Medicine, Lexington, Kentucky.
  • Gedaly R; Division of Transplant, Department of Surgery, University of Kentucky, College of Medicine, Lexington, Kentucky.
J Surg Oncol ; 115(3): 319-323, 2017 Mar.
Article en En | MEDLINE | ID: mdl-27878821
BACKGROUND: Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare primary liver tumor that usually presents in younger patients without underlying liver disease. METHODS: We queried the United Network of Organ Sharing (UNOS) database between October 1988 and January 2013 to evaluate outcomes in patients with FL-HCC undergoing liver transplantation in the United States compared to patients with conventional Hepatocellular Carcinoma (HCC). RESULTS: Sixty-three patients were identified (57% female, mean age 30 years). Only one patient (2%) had an associated Hepatitis C Virus. Mean Model for End-Stage Liver Disease (MELD) score at the time of transplantation was 11.3. Mean waiting time was 325 days and mean cold ischemic time was 6 hr. Overall survival of FL-HCC patients at 1, 3, and 5 years was 96%, 80%, and 48% as compared to HCC patients whose rates were 89%, 77%, and 68%. Six patients had tumor recurrence (10%). The Cox Model demonstrated that MELD and cold ischemic time are the strongest predictors of overall survival in FL-HCC patients. Age and wait time were not associated with poor patient survival in this series. CONCLUSIONS: Good results can be obtained in selected patients transplanted for FL-HCC. FL-HCC patients had similar survival compared to those transplanted for HCC. J. Surg. Oncol. 2017;115:319-323. © 2016 Wiley Periodicals, Inc.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: America do norte Idioma: En Revista: J Surg Oncol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: America do norte Idioma: En Revista: J Surg Oncol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos